Skip to main content
رجوع
Watch Compare

GUIDED THERAPEUTICS INC

جودة البيانات: 100%
GTHP
OTC Manufacturing Measuring & Analyzing Instruments
KWD 0.22
▼ KWD 0.02 (-9.17%)
القيمة السوقية: 23.12 M
السعر
KWD 0.24
القيمة السوقية
23.12 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Revenue grew 75.42% annually over 5 years — strong growth
Negative free cash flow of -1.07 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10781.72%
Capital efficient — spends only 0.26% of revenue on capex

النمو

Revenue Growth (5Y)
75.42%
أعلى من متوسط القطاع (1.92%)
Revenue (1Y)10857.14%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net Margin-416.69%
Op. Margin-309.26%

الأمان

Debt / Equity
N/A
Current Ratio0.12
Interest Coverage-3.84

التقييم

PE (TTM)
-7.24
أقل من متوسط القطاع (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1385 نظير)
المقياس السهم وسيط القطاع
P/E -7.2 -1.5
P/B — 1.6
ROE % — -54.4
Net Margin % -416.7 -41.5
Rev Growth 5Y % 75.4 1.9
D/E — 0.3

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

لا تتوفر تقديرات مستقبلية

مفاجآت الأرباح

آخر 3 أرباع
الربع EPS المقدر EPS الفعلي المفاجأة
Q32013 N/A -KWD 1,279,590.50 —
Q12013 -KWD 640,000.00 -KWD 1,919,385.80 -199.9%
Q42012 -KWD 640,000.00 -KWD 1,279,590.50 -99.9%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 10857.14% Revenue Growth (3Y) 179.76%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 75.42% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 767,000.0 Net Income (TTM) -3.20 M
ROE N/A ROA -346.83%
Gross Margin 74.45% Operating Margin -309.26%
Net Margin -416.69% Free Cash Flow (TTM) -1.07 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.12
Interest Coverage -3.84 Asset Turnover 0.83
Working Capital -5.67 M Tangible Book Value -5.65 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7.24 Forward P/E N/A
P/B Ratio N/A P/S Ratio 30.15
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -4.63%
Market Cap 23.12 M Enterprise Value 23.12 M
Per Share
EPS (Diluted TTM) -0.04 Revenue / Share 0.01
FCF / Share -0.01 OCF / Share -0.01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.26% FCF Conversion 33.48%
SBC-Adj. FCF -1.50 M Growth Momentum 10781.72

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 767,000.0 7,000.0 98,000.0 13,000.0 81,000.0
Net Income -3.20 M -2.42 M -3.49 M -4.34 M -2.07 M
EPS (Diluted) -0.04 -0.05 -0.07 -0.15 -0.18
Gross Profit 571,000.0 2,000.0 36,000.0 -68,000.0 20,000.0
Operating Income -2.37 M -2.11 M -3.46 M -3.33 M -2.36 M
EBITDA — — — — —
R&D Expenses 469,000.0 526,000.0 228,000.0 77,000.0 69,000.0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 617,000.0 381,000.0 278,000.0 582,000.0 1.15 M
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.32 M 1.38 M 1.67 M 3.37 M 2.04 M
Total Liabilities 7.33 M 6.27 M 5.48 M 6.25 M 7.49 M
Shareholders' Equity -6.01 M -4.89 M -3.81 M -2.88 M -5.45 M
Total Debt — — — 0.0 820,000.0
Cash & Equivalents — — — 2.31 M 643,000.0
Current Assets 605,000.0 1.20 M 1.39 M 3.00 M 1.64 M
Current Liabilities 6.64 M 6.16 M 4.81 M 4.87 M 5.69 M